Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Faron Pharmaceuticals Oy ( (GB:FARN) ) is now available.
Faron Pharmaceuticals Ltd has announced the identification of the final patient for its BEXMAB Phase II study, targeting refractory or relapsed myelodysplastic syndrome (r/r MDS) and frontline high-risk MDS. The company expects to report topline efficacy and safety data by April 2025, with detailed findings to be shared at major medical conferences. The study’s interim results have shown promising response rates, significantly surpassing those of existing treatments. Faron is committed to advancing bexmarilimab through clinical development and is considering expanding patient enrollment to strengthen their data set for regulatory purposes.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers. Their lead product, bexmarilimab, is designed to reprogram myeloid cells to overcome cancer immunosuppression, currently being investigated in combination with standard treatments for hematological cancers such as acute myeloid leukemia and myelodysplastic syndrome.
YTD Price Performance: -14.63%
Average Trading Volume: 16,457
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £183.9M
Find detailed analytics on FARN stock on TipRanks’ Stock Analysis page.
